Pipeline
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3 A4 A5
REGN
FY2025 Q4
개선
Regeneron Pharmaceuticals, Inc. 실적 발표
Buzzberg 분석
Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities.
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
Buzzberg 분석 Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities. Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria. 전체 분석 보기분석 접기
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
- Eylea franchise: Eylea-HD is growing but Eylea 2mg faces inevitable decline against upcoming biosimilars; the PFS approval is the next catalyst for Eylea-HD.
- Linezolic is a major near-term pipeline focus, showing high complete response rates in myeloma and amyloidosis; multiple pivotal studies are underway.
- Management is emphasizing its 'Trojan horse' approach to obesity, combining a GLP-GIP agonist with its PCSK9 antibody for dual weight loss and cholesterol reduction.
매출$3.8843B보고값
주당순이익(EPS)$11.44보고값
매출총이익률84.95%보고값
영업이익률22.65%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Clinical Data
First-line metastatic melanoma LAG3 combo readout expected in first half.
Commercial
Liptio adjuvant CSCC launch is off to a great start.
핵심 내용 3개 더 보기
Regulatory
Eylea HD pre-filled syringe decision expected in late April.
Collaboration
Sanofi collaboration development balance expected fully reimbursed by mid-2026.
Guidance
2026 R&D spend guided to $5.9-6.1 billion, up from 2025.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $3.8843B | 보고값 |
| 주당순이익(EPS) | $11.44 | 보고값 |
| 매출총이익률 | 84.95% | 보고값 |
| 영업이익률 | 22.65% | 보고값 |
| 잉여현금흐름 | $0.922B | 보고값 |
| 자본지출 | $0.2487B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | $1.1B–$1.3B | $1.2B | 제시 |
| 매출총이익률 | FY2026 | 83%–84% | 83.5% | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in pipeline breadth, upcoming data readouts, and differentiated product profiles, while acknowledging competitive pressures in certain areas.
투자 및 생산능력
Management expects 2026 capital expenditures to be in the range of $1.1 to $1.3 billion, primarily related to expanding R&D facilities at Tarrytown headquarters and investments in manufacturing network to support the growing commercial portfolio and pipeline.
아래에 언급된 기업 6개 모두 표시
기업발표 이후 수익률
파트너
파트너
Chris Fethmore
Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.
근거
“Total buyer collaboration revenue was $319 million, of which $270 million related to our share of net profits outside the United States.”
파트너
Chris Fethmore
Novartis's high sales of Ilaris triggered the highest royalty tier, boosting Regeneron's other revenue.
근거
“Alaris net sales exceeded $1.5 billion in 2025, achieving the top royalty tier of 15% for the first time.”
파트너
Chris Fethmore
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share. — This is a major profitability inflection point for Regeneron, as its profit share will increase materially in the second half of 2026.
근거
“Dupixent's continued strength enabled a rapid reimbursement of the development balance in 2025, which we now expect to be fully reimbursed by mid-2026.”
경쟁사
경쟁사
Dr. George Yancopoulos
Management highlights a competitor's failure to underscore the uniqueness of Regeneron's antibody discovery technology.
근거
“For example, Amgen, using an inferior humanized mouse approach, tried to make a Dupixent that is starting the same receptor as we did, and their antibody completely failed in all their clinical trials.”
경쟁사
Marion McCourt
Libtayo is gaining market share in first-line non-small cell lung cancer against competing PD-1 immunotherapies.
근거
“new patient market share in this setting greater than Optivo, Tecentric, and Infinsi combined.”
외부 신호
공급망 알파 · 5발표 이후 수익률
Eylea-HD and Eylea wholesaler inventory levels were elevated by ~$30M at end of Q4 2025, expected to negatively impact Q1 2026 net sales.
근거
“wholesaler inventory levels were elevated by approximately 30 million at the end of the fourth quarter for ILEA HD as well as ILEA. We expect first quarter net sales will be negatively impacted as the inventory is absorbed.”
Eylea-HD is now nearly half of total Eylea franchise sales and is growing, but Eylea 2mg is expected to face intense competitive pressure in H2 2026 with biosimilar launches.
근거
“While we anticipate continued growth in ILEA-HD this year, ILEA 2 mg will continue to be under competitive pressure, which is expected to intensify the second half of 2026 as multiple biosimilar products are launched in the United States.”
There is a potential 'Trojan horse' strategy for obesity: a co-formulation of a GLP-GIP with PCSK9 inhibitor to address both weight loss and cholesterol, potentially expanding the market by targeting a broader population.
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share.
The company is expanding into 'next-generation' therapies, aiming to improve upon its existing blockbusters like Dupixent by leveraging its genetics-based antibody discovery and formulation capabilities.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 6개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.